Annovis Bio Stock (NYSE:ANVS)

Forecast Ownership Financials Chart

Previous Close

$1.72

52W Range

$1.54 - $5.50

50D Avg

$1.99

200D Avg

$2.58

Market Cap

$36.00M

Avg Vol (3M)

$1.15M

Beta

1.19

Div Yield

ANVS Company Profile

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

Country

Employees

IPO Date

Jan 29, 2020

Website

ANVS Performance

ANVS Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-29.70M	$-26.69M	$-45.03M
Net Income	$-28.85B	$-24.59M	$-56.20M
EBITDA	$-29.70M	$-26.69M	$-45.03M
Basic EPS	$-1.40	$-2.02K	$-6.23
Diluted EPS	$-1.40	$-2.01K	$-6.23

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
CELU	Celularity Inc.
ELUT	Elutia Inc.
EVAX	Evaxion Biotech A/S
BTAI	BioXcel Therapeutics, Inc.
PDSB	PDS Biotechnology Corporation
BCAB	BioAtla, Inc.
RVPH	Reviva Pharmaceuticals Holdings, Inc.
PYPD	PolyPid Ltd.